Skip to main content

Table 3 Base case result

From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

  Total
Cost JPY (USD)
Incremental
Cost JPY (USD)
QALYs Incremental QALYs ICER JPY/QALYs
(USD/QALYs)
Reactive 39,809   0.6726   
(365.2)    
Preemptive 45,109 5300 0.6755 0.0029 1,843,395
(413.8) (48.6) (16,912)
  1. JPY: Japanease yen, USD: US dollars, QALYs: Qality adjusted life years
  2. 1 USD = 109.0 JPY (2019 annual exchange rate)